Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

KNSA
Kiniksa Pharmaceuticals International, plc Class A
stock NASDAQ

At Close
Jul 28, 2026 3:59:49 PM EDT
79.37USD+24.923%(+15.84)2,874,024
67.58Bid   92.29Ask   24.71Spread
Pre-market
Jul 27, 2026 9:27:30 AM EDT
64.00USD+1.846%(+1.16)0
After-hours
Jul 28, 2026 4:54:30 PM EDT
79.17USD-0.251%(-0.20)400
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:00AM EST  - ARCALYST full-year 2022 guidance to be provided with Q4 2021 financial results -- Vixarelimab Phase 2b data in prurigo nodularis expected in 2H 2022 - KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients -- Year-end 2021 cash reserves expected to fund current operating plan into 2024 -   GlobeNewswire Inc
Jan 3, 2022
04:35PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences, Sotera Health, Eagle Pharma   Benzinga
04:12PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences   Benzinga
04:03PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights   Benzinga
04:01PM EST  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe 40thAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 10, 2022 at 1:30 p.m. Eastern Time.   GlobeNewswire Inc
Dec 29, 2021
04:21PM EST  16:20 Wednesday, December 29, 2021Wedbush (RTTNews) - Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $26 Price Target   RTTNews
08:49AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
06:26AM EST  B of A Securities Maintains Buy on Kiniksa Pharmaceuticals, Lowers Price Target to $34   Benzinga
Dec 28, 2021
08:56AM EST  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Dec. 28, 2021: KNSA, BVXV, FTK, APPS, MBOT   Benzinga
07:16AM EST  Why Kiniksa Pharma Stock Falling In Pre-market?   RTTNews
07:07AM EST  Kiniksa Says Phase 3 Trial Of Mavrilimumab In COVID-19-Related ARDS Fails To Meet Primary Endpoint   RTTNews
07:00AM EST  Kiniksa Announces Phase 3 Trial Of Mavrilimumab In COVID-19-Related ARDS Did Not Meet Primary Efficacy Endpoint   Benzinga
06:59AM EST  Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in   GlobeNewswire Inc
Nov 23, 2021
04:01PM EST  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat atthe Evercore ISI 4th Annual HealthCONx Conference onTuesday, November 30, 2021 at 12:10 p.m. Eastern Time.   GlobeNewswire Inc
Nov 2, 2021
02:32PM EDT  Mid-Afternoon Market Update: Dow Rises Around 150 Points; Semler Scientific Shares Slide   Benzinga
Nov 1, 2021
08:05AM EDT  Kiniksa Pharmaceuticals Q3 EPS $(0.44) Beats $(0.65) Estimate, Sales $12.10M Beat $10.18M Estimate   Benzinga
08:00AM EDT  Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial   GlobeNewswire Inc
04:01AM EDT  Earnings Scheduled For November 1, 2021   Benzinga
Oct 29, 2021
04:01PM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Monday, November 1, 2021, at 8:30 a.m. Eastern Time to report its third quarter 2021 financial results and recent portfolio execution.   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 21, 2021
04:01PM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe 2021 Cantor Fitzgerald Virtual Global Healthcare Conference onTuesday, September 28, 2021 at 10:40 a.m. Eastern Time.   GlobeNewswire Inc
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
08:03AM EDT  Kiniksa Announces Launch of ARCALYST Named Patient Program   Benzinga
08:00AM EDT  - Named Patient Program supports patient access to ARCALYST (rilonacept) in countries where ARCALYST is not currently commercially available -   GlobeNewswire Inc
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
08:11AM EDT  Kiniksa Pharmaceuticals Q2 EPS $(0.61) Beats $(0.79) Estimate   Benzinga
08:00AM EDT  - Q2 2021 ARCALYST (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians -   GlobeNewswire Inc
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Aug 2, 2021
04:01PM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe 2021 Wedbush PacGrow Healthcare Conference onTuesday, August 10, 2021 at 2:55 p.m. Eastern Time.   GlobeNewswire Inc
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 20, 2021
04:01PM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. Eastern Time to report its second quarter 2021 financial results and recent corporate and portfolio activity.   GlobeNewswire Inc
Jun 9, 2021
09:14AM EDT  The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US   Benzinga
Jun 8, 2021
04:01PM EDT  Kiniksa Reports US Patent Issued For Treatment Of Recurrent Pericarditis   Benzinga
04:01PM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST (rilonacept) in the treatment of recurrent pericarditis.   GlobeNewswire Inc
07:34AM EDT  Kiniksa Outlines Next Steps For Development Of Mavrilimumab   Benzinga
07:30AM EDT  - Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications -   GlobeNewswire Inc
Jun 1, 2021
04:01PM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe Goldman Sachs 42nd Annual Global Healthcare ConferenceonTuesday, June 8, 2021 at 9:40 a.m. Eastern Time.   GlobeNewswire Inc
May 27, 2021
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 26, 2021
07:33AM EDT  The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing   Benzinga
May 25, 2021
07:53AM EDT  The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 4, 2021
08:18AM EDT  Kiniksa Pharmaceuticals Q1 EPS $(0.72) Down From $(0.48) YoY   Benzinga
08:00AM EDT  Kiniksa Reports First Quarter 2021 Financial Results and Recent   GlobeNewswire Inc
08:00AM EDT  Kiniksa Announces Final Data from Phase 1 Trial of KPL-404; CEO Says Final Data 'are very encouraging, as they confirm and extend the findings from the previously-reported lower-dose cohorts'   Benzinga
07:59AM EDT  Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404   GlobeNewswire Inc
Apr 12, 2021
07:31AM EDT  Kiniksa Announces Announces Mavrilimumab Phase 2 Trial In Non-Mechanically Ventilated Severe COVID-19 Patients Achieved Primary Efficacy Endpoint   Benzinga
07:30AM EDT  Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial   GlobeNewswire Inc
Apr 1, 2021
08:09AM EDT  Kiniksa Pharmaceuticals Announces Commercial Availability of ARCALYST For Recurrent Pericarditis   Benzinga
08:00AM EDT  - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis - ARCALYST now available on prescription basis in the U.S. - Kiniksa One Connect program provides ongoing patient access and support services   GlobeNewswire Inc
Mar 19, 2021
10:43AM EDT  Kiniksa Pharmaceuticals shares were trading higher after the company announced FDA approval of ARCALYST for recurrent pericarditis.   Benzinga
07:46AM EDT  The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs   Benzinga
Mar 18, 2021
04:30PM EDT  Kiniksa Pharma Reports FDA Approval Of ARCALYST For Recurrent Pericarditis   Benzinga
04:30PM EDT  - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -- Commercial launch expected in April 2021-- Kiniksa launches Kiniksa One Connect patient support program -- Conference call and webcast scheduled for5:30 p.m. EDTtoday -   GlobeNewswire Inc
03:50PM EDT  FDA Says Approved Arcalyst Injection To Treat Recurrent Pericarditis, Reduce Risk Of Recurrence In Adults & Children 12 Years And Older; FDA Says Granted Approval Of Arcalyst To Kiniksa Pharmaceuticals   Benzinga
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Mar 3, 2021
04:33PM EST  Kiniksa Pharma 8-K Shows Co.'s UK Unit Entered Commercial Supply Deal With Regeneron For Regeneron's Exclusive Right To Manufacture, Supply Of Rilonacept   Benzinga
Mar 2, 2021
08:26AM EST  Kiniksa Launches Patient Registry For Recurrent Pericarditis   Benzinga
08:00AM EST  Kiniksa Launches Patient Registry (RESONANCE) for Recurrent   GlobeNewswire Inc
Feb 28, 2021
11:38AM EST  Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates   Benzinga
Feb 23, 2021
08:12AM EST  Kiniksa Pharmaceuticals Q4 EPS $(0.79) Down From $(0.58) YoY   Benzinga
08:00AM EST  Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial   GlobeNewswire Inc
Jan 11, 2021
08:10AM EST  Kiniksa Highlights Corporate Priorities And Expected 2021 Milestones   Benzinga
08:00AM EST  - PDUFA goal date of March 21, 2021 for rilonacept in recurrent pericarditis -- Data from Phase 2 portion of mavrilimumab Phase 2/3 trial in severe COVID-19 pneumonia and hyperinflammation expected in 1H 2021 -- Final Phase 1 KPL-404 data expected in 1H 2021 -   GlobeNewswire Inc
Jan 4, 2021
04:20PM EST  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe 39thAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 11, 2021 at 4:30 p.m. Eastern Time.   GlobeNewswire Inc
Dec 22, 2020
08:03AM EST  Kiniksa Announces Data From US Investigator-Initiated Study Of Mavrilimumab In Severe COVID-19 Pneumonia And Hyperinflammation   Benzinga
08:00AM EST  - Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab   GlobeNewswire Inc
Dec 15, 2020
08:10AM EST  Kiniksa Reports Commencement Of Dosing Of Vixarelimab Phase 2b Trial In Prurigo Nodularis   Benzinga
08:00AM EST  Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in   GlobeNewswire Inc
Nov 30, 2020
08:02AM EST  Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404   Benzinga
08:00AM EST  -Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous   GlobeNewswire Inc
Nov 24, 2020
08:00AM EST  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st, 2020 at 8:50 a.m. Eastern Time.   GlobeNewswire Inc
Nov 23, 2020
08:01AM EST  Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis   Benzinga
08:00AM EST  -PDUFA goal date of March 21, 2021-- Filing based on positive data from RHAPSODY, which achieved its primaryand all major secondary endpoints -- Rilonacept BLA for CAPS transferred to Kiniksa from Regeneron -   GlobeNewswire Inc
Nov 17, 2020
08:05AM EST  Kiniksa Pharma Highlights Publication Of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020 In New England Journal Of Medicine   Benzinga
08:00AM EST  Kiniksa Announces New England Journal of Medicine Publication of   GlobeNewswire Inc
Nov 16, 2020
08:15AM EST  Kiniksa Announces Breakthrough Therapy Designation Granted To Vixarelimab For Treatment Of Pruritus Associated With Prurigo Nodularis   Benzinga
08:00AM EST  Kiniksa Announces Breakthrough Therapy Designation Granted to   GlobeNewswire Inc
Nov 9, 2020
04:07PM EST  Kiniksa Announces American College Of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation Of Mavrilimumab Phase 2 Giant Cell Arteritis Data   Benzinga
04:01PM EST  Kiniksa Announces American College of Rheumatology Convergence   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
07:45AM EST  Kiniksa Pharmaceuticals Q3 EPS $(0.66) Down From $(0.49) YoY   Benzinga
07:30AM EST  -- Rilonaceptcommercial launchin recurrent pericarditis anticipated in 1H 2021, if approvedby the FDA -- Mavrilimumab Phase 2 trial in GCA achieved primary and secondary efficacy endpoints with statistical significance -- All cohorts have been dosedin the KPL-404(anti-CD40)Phase 1 study -- Cash reserves of approximately $364 million expected to fund current operating plan into2023   GlobeNewswire Inc
Oct 29, 2020
08:22AM EDT  Kiniksa Announces Phase 2 Clinical Data From Vixarelimab In Prurigo Nodularis To Be Presented At European Academy Of Dermatology And Venereology Virtual Congress   Benzinga
08:00AM EDT  Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in   GlobeNewswire Inc
Oct 26, 2020
08:15AM EDT  Kiniksa To Present New Data From Phase 2 Trial Of Mavrilimumab In Giant Cell Arteritis To Be Presented At Late-Breaking Abstracts Session Of American College Of Rheumatology Convergence 2020   Benzinga
08:00AM EDT  -Mavrilimumab reducedtime-to-flare and increasedsustained remission in Phase 2 giant cell arteritisclinical trial --Primary and secondary efficacy endpoints achieved statistical significance --Results were consistent across new onset and relapsing/refractory cohorts -   GlobeNewswire Inc
Oct 6, 2020
10:17AM EDT  Shares of Kiniksa Pharmaceuticals, Ltd. (KNSA) are gaining over 15% on Tuesday morning after the drug maker announced positive data from a mid-stage study of mavrilimumab in giant cell arteritis.   RTTNews
08:05AM EDT  Kiniksa Announces Data From Phase 2 Trial Of Mavrilimumab In Giant Cell Arteritis; Trial Achieved Both The Primary And Secondary Efficacy Endpoints With Statistical Significance   Benzinga
08:00AM EDT  Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab   GlobeNewswire Inc
Sep 24, 2020
04:13PM EDT  Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th   GlobeNewswire Inc
Sep 21, 2020
08:00AM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the company will host a virtual Rilonacept Analyst Day on Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. Eastern Daylight Time.   GlobeNewswire Inc
Sep 15, 2020
08:20AM EDT  Kiniksa Announces U.S. Orphan Drug Designation For Mavrilimumab For The Treatment Of Giant Cell Arteries   Benzinga
08:00AM EDT  Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab   GlobeNewswire Inc
Sep 9, 2020
04:01PM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16th, 2020 at 2:00 p.m. Eastern Time.   GlobeNewswire Inc
Sep 8, 2020
04:22PM EDT  Kiniksa Pharma S-3 Shows Registration For ~1.48M Share Common Stock Offering Via Selling Shareholders   Benzinga
Aug 31, 2020
08:00AM EDT  Kiniksa Presents Data on the Burden of Disease in Patients with   GlobeNewswire Inc
Aug 4, 2020
08:00AM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11th, 2020 at 1:10 p.m. Eastern Time.   GlobeNewswire Inc
Jul 30, 2020
09:07AM EDT  Kiniksa Pharmaceuticals Q2 EPS $(0.65) Up From $(0.68) YoY   Benzinga
07:30AM EDT  Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year   GlobeNewswire Inc
Jul 22, 2020
05:45AM EDT  Kiniksa Pharmaceuticals Prices 5.9M Share Upsized Public Offering @$21/Share   Benzinga
Jul 21, 2020
09:55PM EDT  Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public   GlobeNewswire Inc
Jul 20, 2020
04:08PM EDT  Kiniksa Pharmaceuticals Announces A Common Stock Offering Of $100 Million   Benzinga
04:07PM EDT  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa, we, and our) announced today that it is commencing a public offering of $100.0 million of Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional Class A common shares. All of the Class A common shares are being offered by Kiniksa.   GlobeNewswire Inc
Jul 16, 2020
10:10AM EDT  Kiniksa Pharmaceuticals shares are trading higher after the company announced US Orphan Drug Designation for Rilonacept for the treatment of pericarditis.   Benzinga
07:40AM EDT  Kiniksa: FDA Grants U.S. Orphan Drug Designation For Rilonacept For The Treatment Of Pericarditis   RTTNews
07:32AM EDT  Kiniksa Announces US Orphan Drug Designation For Rilonacept For The Treatment Of Pericarditis   Benzinga
07:30AM EDT  Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC